BetaShares Global Healthcare ETF - Currency Hedged (ASX: DRUG) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


BetaShares Global Healthcare ETF - Currency Hedged Chart and Price Data

Fundamentals Data provided by Morningstar.

Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

  • BetaShares Global Healthcare ETF - Currency Hedged (ASX: DRUG)
    Latest News

    A fit man flexes his muscles, indicating a positive share price movement on the ASX market

    How to invest in US weight loss drug stocks on the ASX

    Want to buy shares in the maker of Ozempic? There's an ASX ETF for that.

    Read more »

    Shot of two young scientists using a laptop in a laboratory.
    Healthcare Shares

    How can ASX investors buy the US stock the WHOLE world is talking about?

    Want to know how to buy the international stock du jour from the comfort of the ASX? Read on!

    Read more »

    medical asx share price represented by doctor giving thumbs up

    'Beyond our expectations': How to invest in obesity drugs like Ozempic with ASX ETFs

    This could be your way to invest in obesity drugs.

    Read more »

    Man holding sign saying economic slowdown, ASX shares, afterpay shares

    3 defensive ASX ETFs to buy if a recession comes

    These could be top options for investors concerned about a recession.

    Read more »

    The letters ETF with a man pointing at it.

    Expert names 2 excellent ASX ETFs to buy

    Here's why these ASX ETFs could be top options for investors in the current economic environment.

    Read more »

    Man looking at an ETF diagram.

    Expert names the ETFs to buy this month

    These ETFs could be top options for investors in this uncertain economic environment.

    Read more »

    A shocked man sits at his desk looking at his laptop while talking on his mobile phone with declining arrows in the background representing falling ASX 200 shares today

    Betashares names 6 'defensive' ASX ETFs to consider for a possible recession

    Here are the ETFs to buy if you're concerned about an impending recession.

    Read more »

    Stethoscope with a piggy bank and hundred dollar notes.

    A defensive ASX ETF for a recessionary environment: experts

    In an ageing world newly aware of the potential threats posed by pandemics, healthcare shares have received plenty of attention…

    Read more »

    Share Market News

    ETF provider VanEck to launch 4 new ASX ETFs

    ETF provider VanEck has just announced 4 new ETFs will soon hit the ASX boards. Find out which of these…

    Read more »

    DRUG ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Edward Sippel Non-Executive Director Mar 2021
    No Profile Reported in Annual Report.
    Mr Alex Vynokur Executive Director Sep 2009
    Mr Vynokur is responsible for leading the strategy and overall management of the business. Alex was involved in the establishment and development of several Australian financial services businesses including Pengana Capital and Centric Wealth. Alex is a director and principal of Apex Capital Partners. He is also a director of Toranotec Ltd. Alex previously worked at Turnbull Pillemer Capital, where he focussed on identifying and managing investments across the financial services industry. Prior to commencing his career in financial services, Alex was a lawyer at Baker & McKenzie, specialising in mergers and acquisitions and financial services.
    Mr Jason Gellert Executive Director Mar 2021
    Mr Gellert worked in the private equity advisory group at Morgan Stanley in New York and their mergers and acquisitions group in Sydney. He also worked in the investment team at Investec Wentworth Private Equity. Jason's experience spans mergers and acquisitions, capital markets and general corporate advice, as well as funds management.

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    No Top 20 Shareholder Information 0 0.00%